- **EBD Growth Resilience**: 2% year-over-year increase in energy-based devices revenue, offsetting broader market softness.
- **Innovative Product Launch**: Venus NOVA platform targeting GLP-1 users, set for limited commercial release in December 2025.
- **Balance Sheet Strengthening**: $9.6 million debt reduction and $5.9 million cash on hand, despite $22.6 million net loss.
- **Hair Business Drag**: 12% decline inHair system sales and ongoing challenges with the MHG Co. Ltd. sale.

**【CEO Summary Section】**
- **EBD Revenue Growth**: Energy-based devices (EBD) revenue increased 2% year-over-year to $9.5 million, driven by strong execution in the U.S. market, particularly for core products like Bliss MAX and Versa PRO.
- **Venus NOVA Launch**: Announced 510(k) clearance for Venus NOVA, a next-generation multi-application platform for body and skin treatments, targeting GLP-1 users and unmet aesthetic needs. Limited commercial launch expected in December 2025.
- **Balance Sheet Improvements**: Reduced debt by $9.6 million through debt-to-equity exchanges and amendments to the Madryn Asset Management bridge loan facility. Cash and cash equivalents reached $5.9 million.
- **Hair Business Challenges**: Total revenue declined 8% year-over-year to $13.8 million, withHair system sales down 12% due to economic uncertainty and delays in the MHG Co. Ltd. sale.

**【CFO Financial Commentary】**
- **Revenue Performance**: U.S. revenue decreased 12% year-over-year, while international revenue fell 3%. Cash sales represented 73% of systems and subscription revenue, up from 76% in the prior year.
- **Gross Profit**: Decreased 11% to $8.8 million, with gross margin at 64% (down from 66.1% in 2024) due to U.S. tariffs and higher manufacturing costs.
- **Operating Expenses**: Increased 7% to $18.3 million, driven by legal fees related to theHair sale and inflationary pressures. Adjusted EBITDA loss widened to $7.8 million.
- **Net Loss**: $22.6 million, reflecting $12.5 million in non-cash losses on debt extinguishment and subsidiary disposal.
- **Liquidity**: $5.9 million in cash, with $30.1 million in total debt obligations as of September 30, 2025.

**【Q&A Highlights】**
- No questions were asked during the session, as the call concluded immediately after CFO remarks.

Venus Concept Inc. (VERO) Q3 2025 Earnings Call Transcript

- **Strategic Sale Success**: $20M divestiture of Venous Hair business to focus on core aesthetics, enhancing cash flow and profitability.
- **Revenue Resilience**: U.S. cash system sales up 23% YoY, offsetting international headwinds, signaling stabilization.
- **Financial Improvement**: Reduced debt by $5.4M YoY, cash position strengthened, and cost management flattening operating expenses QoQ.
- **Growth Catalysts**: New body device launch in 2026 to tap into GLP-1 weight loss trends, positioning for long-term growth.

**【CEO Summary Section】**
- **Q2 2025 Performance**: Revenue grew 15% sequentially but declined 5% YoY, driven by a 23% YoY increase in U.S. cash system sales and a 18% YoY decline in international markets due to tariffs and macroeconomic challenges.
- **Strategic Initiatives**: Sold the Venous Hair business for $20 million to Meta Health Group, aiming to refocus on core medical aesthetics and improve profitability. U.S. cash system sales now account for 65% of total systems, up from 58% YoY.
- **Future Outlook**: Planning to launch a new body device in early 2026 to capitalize on GLP-1 weight loss trends. Maintaining disciplined cost management and exploring further strategic alternatives.

**【CFO Financial Commentary】**
- **Revenue**: Q2 2025 total revenue $15.7 million (-5% YoY), with U.S. revenue up 5% YoY and international down 18% YoY.
- **Gross Profit**: $9.4 million (-20% YoY), gross margin 60.1% (down from 71.5% YoY) due to supply chain disruptions and lower-margin sales mix.
- **Operating Expenses**: $18.5 million (+6% YoY), but flat QoQ, reflecting cost containment efforts.
- **Balance Sheet**: Cash $4.9 million, debt $34.3 million (down from $39.7 million YoY). Raised $3.9 million in equity and exchanged $17.5 million of debt for preferred stock.
- **Adjusted EBITDA**: Loss of $8.8 million (worsened from $4.1 million YoY).

Venus Concept Inc. (VERO) Q2 2025 Earnings Call Transcript

- **Revenue decline accelerates**: Q1 2025 revenue down 22% YoY to $13.6M, driven by 25% system sales drop and distributor hesitancy.
- **Strategic shift paying off**: U.S. cash system sales now 80% of total (vs. 75% last year), improving margin profile.
- **New product momentum**: Body contouring device launch expected Q2 2025, with strong customer excitement and potential 1-2.5% margin impact from tariffs.
- **Financial stabilization**: $2.7M equity raise post-quarter and $4.2M debt reduction, though cash balance remains low at $3.2M.
- **Q2 outlook cautious**: Sequential revenue growth expected but no full-year guidance due to macro uncertainty.


**【CEO Summary Section】**
- Q1 2025 revenue declined 22% YoY to $13.6 million, driven by 25% drop in system sales and distributor hesitancy in international markets.
- U.S. cash system sales accounted for 80% of total U.S. systems (vs. 75% last year), reflecting strategic focus on high-margin cash transactions.
- New body contouring device expected to launch in early H2 2025, with strong customer anticipation based on feedback from existing products.
- Company secured $2.7 million in equity financing post-quarter and reduced debt by $4.2 million to $35.5 million.

**【CFO Financial Commentary】**
- GAAP net loss widened to $12.4 million (-26% YoY), with adjusted EBITDA loss of $8.3 million (vs. $5.1 million prior year).
- Gross margin contracted to 54.2% (from 66.6% YoY), due to tighter lending practices and lower international revenue.
- Operating expenses decreased 6% to $18.3 million, reflecting cost containment efforts.
- Cash balance of $3.2 million as of Q1 end, with $10 million bridge loan amendment secured post-quarter.

**【Q&A Key Takeaways】**
- Tariffs on Israeli-manufactured products could reduce gross margin by 1-2.5% in 2025, but indirect impacts from distributor hesitancy are more significant.
- Q1 system sales delays (pushed to Q2) were evenly split between U.S. direct and international distributor channels.
- New body device launch on track for early H2 2025; expects 'meaningful market uptake' leveraging existing customer base and feedback from current products.
- No full-year 2025 guidance provided due to macroeconomic uncertainty, but expect sequential revenue growth in Q2.


Venus Concept Inc. (VERO) Q1 2025 Earnings Call Transcript

- **Strategic Shift Drives Cash Sales Growth**: U.S. cash system sales rose 27% YoY, accounting for 87% of Q4 2024 U.S. system revenue, despite overall revenue decline.
- **Debt Reduction and Balance Sheet Improvement**: Total debt decreased 47% YoY to $39.7 million, enhancing financial flexibility.
- **New Product Pipeline**: H2 2025 launch of a new body device and continued R&D in Venus Hair robots to drive future growth.
- **Macroeconomic Challenges**: Tight credit markets and supply chain shortages impacted Q4 system sales, but cost management reduced cash used in operations by 14% YoY.


**【CEO Summary Section】**
- Q4 2024 revenue declined 13% YoY to $15.8 million, driven by a strategic shift to prioritize cash system sales over subscriptions. U.S. cash system sales grew 27% YoY, accounting for 87% of total U.S. system revenue, up from 58% in Q4 2023.
- Global macroeconomic challenges (e.g., customer financing pressures, higher interest rates) and supply chain shortages impacted system adoption. However, international distributor sales doubled YoY, driven by demand in APAC and EMEA.
- Fiscal 2024 total revenue declined 15% YoY, with 60% of the decline attributed to the strategic shift away from subscription sales. The company expects a more normalized business profile in 2025, with reduced strategic disruption.
- Key initiatives include: (1) debt reduction (total debt down 47% YoY to $39.7 million), (2) leadership restructure to streamline decision-making, (3) Venus Hair robot R&D progress, and (4) a new body device launch planned for H2 2025.

**【CFO Financial Commentary】**
- Q4 2024 GAAP net loss was $8 million, narrower than Q4 2023's $11.1 million loss. Adjusted EBITDA loss was $6.1 million vs. $5.9 million in Q4 2023.
- Cash systems and product/service revenue grew 10% YoY, while lease revenue declined 58% YoY. Gross margin improved to 69.1% (from 66.5% in Q4 2023) due to cost management and revenue mix shifts.
- Operating expenses decreased 11% YoY to $17.6 million, driven by reductions in G&A (-13%), sales/marketing (-8%), and R&D (-12%).
- Cash used in operations rose $3.8 million in Q4 2024 (vs. $0.8 million in Q4 2023), partially due to inventory advances to mitigate supply chain shortages.

**【Q&A Highlights】**
- **2025 Growth Strategy**: Focus on stabilizing international distributor orders, launching a new body device in H2 2025, and leveraging Venus Prime financing program to differentiate from competitors.
- **Venus Hair Performance**: ARTAS robot sales remain strong, with R&D investments in new innovations. The business has attracted strategic interest due to its high price point and customer demand.
- **Cost Structure**: Current infrastructure is lean and scalable; no major cost-cutting opportunities remain. Variable expenses (e.g., marketing) will expand with sales growth.
- **Tariff Impact**: U.S.-manufactured robots and Israel-manufactured energy devices are minimally affected by tariffs, as Israel is protected under U.S. trade agreements.


Actual									-277.2	-64.35	-29.7	-56.1	-28.05	1.65	-29.7	-13.2	-21.45	-26.4	-36.3	-23.1	-20.35	-14.85	-18.04	-22.11	-18.48	-33.55	-14.08	-11.23	-17.44	-8.03	-12.14
Forecast									-117.15	-57.75	-36.7125	-29.37	-24.42	-20.13	-20.2587	-15.9968	-14.6768	-8.9183	-24.5685	-22.616	-23.6335	-16.8989	-16.5887	-13.0181	-16.8681	-16.0321	-12.4799	-10.0089	-14.62	-9.72	-3.61
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-136.62%	-11.43%	+19.10%	-91.01%	-14.86%	+108.20%	-46.60%	+17.48%	-46.15%	-196.02%	-47.75%	-2.14%	+13.89%	+12.12%	-8.75%	-69.84%	-9.56%	-109.27%	-12.82%	-12.20%	-19.29%	+17.39%	-236.29%

VERO(Delisted)

VERO fundamentals

VERO Q3 2025 Earnings

Earnings Call

You can ask Aime